S Schulman

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. doi request reprint How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
    Blood 119:3016-23. 2012
  2. ncbi request reprint Extension of anticoagulation after venous thromboembolism - risk factors influencing the decision
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada, and Coagulation Unit, Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Hamostaseologie 28:110-9. 2008
  3. ncbi request reprint New oral anticoagulant agents - general features and outcomes in subsets of patients
    Sam Schulman
    Sam Schulman, Thrombosis Service, HHS General Hospital, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada, Tel 1 905 5270271, ext 44479, Fax 1 905 5211551, E mail
    Thromb Haemost 111:575-82. 2014
  4. doi request reprint Adherence to anticoagulant treatment with dabigatran in a real-world setting
    S Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, 237 Barton Street East, Hamilton, Ontario, Canada
    J Thromb Haemost 11:1295-9. 2013
  5. ncbi request reprint Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion
    S Schulman
    Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada Department of Medicine, Thrombosis Service, McMaster University, Hamilton, ON, Canada
    Thromb Res 131:300-3. 2013
  6. doi request reprint Optimal duration of anticoagulant therapy
    Sam Schulman
    Division of Hematology and Thromboembolism, Department of Medicine, Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences Hamilton General Site, McMaster University, Hamilton, Ontario, Canada
    Semin Thromb Hemost 39:141-6. 2013
  7. doi request reprint New anticoagulants in atrial fibrillation management
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
    Thromb Res 131:S63-6. 2013
  8. ncbi request reprint Extended use of dabigatran, warfarin, or placebo in venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
    N Engl J Med 368:709-18. 2013
  9. doi request reprint Pharmacologic tools to reduce bleeding in surgery
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Hematology Am Soc Hematol Educ Program 2012:517-21. 2012
  10. ncbi request reprint Advances in the management of venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
    Best Pract Res Clin Haematol 25:361-77. 2012

Collaborators

Detail Information

Publications108 found, 100 shown here

  1. doi request reprint How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
    Blood 119:3016-23. 2012
    ..Unfortunately, there is a limited evidence base to inform decisions around management of these agents. We present our practice in these settings supported, where available, with literature evidence...
  2. ncbi request reprint Extension of anticoagulation after venous thromboembolism - risk factors influencing the decision
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada, and Coagulation Unit, Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Hamostaseologie 28:110-9. 2008
    ....
  3. ncbi request reprint New oral anticoagulant agents - general features and outcomes in subsets of patients
    Sam Schulman
    Sam Schulman, Thrombosis Service, HHS General Hospital, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada, Tel 1 905 5270271, ext 44479, Fax 1 905 5211551, E mail
    Thromb Haemost 111:575-82. 2014
    ..Finally, a strategy of how to select patients for warfarin or the new anticoagulants and thereafter possibly also among the latter is outlined. ..
  4. doi request reprint Adherence to anticoagulant treatment with dabigatran in a real-world setting
    S Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, 237 Barton Street East, Hamilton, Ontario, Canada
    J Thromb Haemost 11:1295-9. 2013
    ..In clinical trials, adherence to a prescribed regimen with dabigatran was enhanced by frequent follow-up visits and pill counts...
  5. ncbi request reprint Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion
    S Schulman
    Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada Department of Medicine, Thrombosis Service, McMaster University, Hamilton, ON, Canada
    Thromb Res 131:300-3. 2013
    ..In patients with a high risk for stroke and having invasive procedures with a high risk for bleeding it is unclear how anticoagulant therapy should be managed...
  6. doi request reprint Optimal duration of anticoagulant therapy
    Sam Schulman
    Division of Hematology and Thromboembolism, Department of Medicine, Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences Hamilton General Site, McMaster University, Hamilton, Ontario, Canada
    Semin Thromb Hemost 39:141-6. 2013
    ..The balancing of thrombotic versus bleeding risk is based on some typical patient scenarios. Examples of risk prediction tools are also provided...
  7. doi request reprint New anticoagulants in atrial fibrillation management
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
    Thromb Res 131:S63-6. 2013
    ..This review addresses the interaction of various patient characteristics with the treatment and what features can assist the physician in the choice of anticoagulant for the individual patient...
  8. ncbi request reprint Extended use of dabigatran, warfarin, or placebo in venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
    N Engl J Med 368:709-18. 2013
    ..Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism...
  9. doi request reprint Pharmacologic tools to reduce bleeding in surgery
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Hematology Am Soc Hematol Educ Program 2012:517-21. 2012
    ....
  10. ncbi request reprint Advances in the management of venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
    Best Pract Res Clin Haematol 25:361-77. 2012
    ..The VKAs have been subjected to many randomised trial addressing the initiation, intensity, monitoring and self-management. Extended anticoagulation and the selection for that is finally reviewed...
  11. doi request reprint Treatment of venous thromboembolism with dabigatran
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
    Curr Opin Pulm Med 18:410-5. 2012
    ..This article reviews the data and, where applicable, compares them with other novel oral anticoagulants, particularly rivaroxaban, for which all phase III trials have been published...
  12. doi request reprint Is the warfarin saga over?
    S Schulman
    Thrombosis Service, HHS General Hospital, Hamilton, ON, Canada
    J R Coll Physicians Edinb 42:51-5. 2012
    ..This review discusses the directions we could follow in such a tailored anticoagulation approach, referring to the limited evidence when available...
  13. doi request reprint The oral thrombin inhibitor dabigatran: strengths and weaknesses
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
    Semin Thromb Hemost 38:7-15. 2012
    ..Laboratory testing for dabigatran will not be discussed in any detail in this article, which is instead the focus of other articles from this issue of Seminars in Thrombosis & Hemostasis...
  14. ncbi request reprint Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial
    Sam Schulman
    McMaster University, Thrombosis and Atherosclerosis Research Institute, and Ontario Clinical Oncology Group, Hamilton, Ontario, Canada
    Ann Intern Med 155:653-9, W201-3. 2011
    ..Guidelines recommend that patients receiving warfarin undergo international normalized ratio (INR) monitoring every 4 weeks...
  15. ncbi request reprint An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency
    S Schulman
    Coagulation Unit, Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Haemophilia 12:223-7. 2006
    ..A bolus dose of 20 microg kg(-1) and thereafter maintenance of the FVII activity at approximately 3 IU mL(-1) appears effective and safe...
  16. ncbi request reprint Anticoagulants and their reversal
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Transfus Med Rev 21:37-48. 2007
    ..Additional options that may become available in the future are also discussed briefly...
  17. doi request reprint Direct and indirect costs of management of long-term warfarin therapy in Canada
    S Schulman
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 8:2192-200. 2010
    ..The aim of the present study was to assess total costs of warfarin-based anticoagulation in different health care models...
  18. ncbi request reprint Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII
    Sam Schulman
    Coagulation Unit, Department of Haematology, Karolinska University Hospital, Stockholm, Sweden
    Thromb Haemost 94:1177-80. 2005
    ..This mode of substitution was therefore safe, effective and well tolerated...
  19. ncbi request reprint New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 96:258-66. 2006
    ..The conclusions drawn should help clinicians make balanced decisions on the optimal duration of anticoagulation after an episode of VTE...
  20. ncbi request reprint Thromboprophylaxis in medical patients--why not for all?
    Sam Schulman
    Dept of Medicine, McMaster University, Hamilton, Canada
    Pathophysiol Haemost Thromb 35:141-5. 2006
    ..The agents are generally safe, with only a small increase of major bleeding, less with LMWH than with unfractionated heparin. The challenge is still to direct the efforts to the most appropriate patients...
  21. ncbi request reprint New aspects on treatment modalities for thromboembolic episodes
    S Schulman
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    J Intern Med 268:109-19. 2010
    ..This review focuses on the novel therapies for VTE although the new anticoagulants will also play a major role in the management of arterial disease, which will be briefly presented...
  22. ncbi request reprint Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months
    S Schulman
    Department of Hematology, Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 4:734-42. 2006
    ..The influence of the duration of anticoagulant therapy after venous thromboembolism (VTE) on the long-term morbidity and mortality is unclear...
  23. doi request reprint Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
    S Schulman
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 8:202-4. 2010
    ..The intention is to seek approval of this definition from the regulatory authorities to enhance its incorporation into future clinical trial protocols...
  24. ncbi request reprint The role of ximelagatran in the treatment of venous thromboembolism
    Sam Schulman
    Department of Haematology, Karolinska University Hospital, Stockholm, Sweden
    Pathophysiol Haemost Thromb 34:18-24. 2005
    ....
  25. doi request reprint Dabigatran etexilate: future directions in anticoagulant treatment
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Clin Appl Thromb Hemost 15:32S-41S. 2009
    ....
  26. doi request reprint Rivaroxaban in orthopedic surgery--a change of paradigm?
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Clin Appl Thromb Hemost 15:613-20. 2009
    ..Whether the introduction of rivaroxaban is a change of paradigm will ultimately be decided in the eyes and mind of the beholder...
  27. doi request reprint Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range
    S Schulman
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Thromb Res 125:393-7. 2010
    ..Well-controlled patients on warfarin may still have occasional International Normalized Ratios (INRs) outside the therapeutic range. It is unclear whether there is any benefit of a single-dose correction in this situation...
  28. doi request reprint The plasma concentration of activated protein C appears normal in patients with haemophilia
    S Schulman
    Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Haemophilia 15:566-70. 2009
    ..Patients with haemophilia appear to generate normal concentrations of APC during basal conditions. APC does not seem to be an important modulator of the phenotypic expression of haemophilia...
  29. pmc Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Thromb J 6:15. 2008
    ..We sought to identify easily available clinical characteristics that may influence the rate of normalization of prothrombin time when warfarin is stopped before surgery or invasive procedures...
  30. ncbi request reprint [Bleeding time--only in special cases. The method is of little value as a general screening analysis]
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, Kanada
    Lakartidningen 105:1268. 2008
  31. doi request reprint Current strategies in prophylaxis and treatment of venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Ann Med 40:352-9. 2008
    ..Although new, orally available anticoagulants without need for monitoring or dose adjustments have been in clinical trials for a decade, none is approved yet, and will not be discussed in this review...
  32. doi request reprint Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, ON, Canada
    N Engl J Med 361:2342-52. 2009
    ..The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism...
  33. doi request reprint A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery
    Sam Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
    Drug Saf 34:449-63. 2011
    ....
  34. doi request reprint Validation of a composite score for clinical severity of hemophilia
    S Schulman
    Coagulation Unit, Department of Hematology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 6:1113-21. 2008
    ..Evaluation of modulators of the phenotypic expression of hemophilia may benefit from a scoring system that reflects several aspects of the clinical severity instead of only one dimension...
  35. doi request reprint Clinical factors influencing the sensitivity to warfarin when restarted after surgery
    S Schulman
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    J Intern Med 263:412-9. 2008
    ..Knowledge of the clinical determinants of postoperative response could help avoid excessive anticoagulation in sensitive patients or avoid extended delays in achieving a therapeutic level in resistant patients...
  36. ncbi request reprint Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study
    Sam Schulman
    Department of Medicine, McMaster University, Hamilton, Canada
    Thromb Haemost 94:820-4. 2005
    ..36, 1.93; P = 0.7). This complementary follow-up analysis confirms the benefit of oral ximelagatran 24 mg twice daily, administered without coagulation monitoring or dose adjustment, for the long-term secondary prevention of VTE...
  37. ncbi request reprint Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
    S Schulman
    Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 3:692-4. 2005
    ..The intention is to also seek approval of this definition from the regulatory authorities...
  38. ncbi request reprint Minimizing factor requirements for surgery without increased risk
    S Schulman
    Department of Hematology, Coagulation Unit, Karolinska University Hospital, S 171 76 Stockholm, Sweden
    Haemophilia 10:35-40. 2004
    ..In addition, we review the possibilities to reduce the amount of factor concentrate by performing a combination of orthopaedic procedures and using local haemostatic agents or antifibrinolytic agents...
  39. doi request reprint Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding
    S Schulman
    Department of Medicine, McMaster University and Henderson Research Center, Hamilton, ON, Canada
    J Thromb Haemost 8:641-50. 2010
    ..However, as the patient slowly stabilizes after appropriate interventions, it is necessary to de-escalate the treatment in accordance with decreasing net benefit of prolonged combination therapy...
  40. doi request reprint Advantages and limitations of the new anticoagulants
    S Schulman
    Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada Karolinska Institutet, Stockholm, Sweden
    J Intern Med 275:1-11. 2014
    ..This review should clarify some of these concerns. ..
  41. doi request reprint Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study
    Y K Kim
    Department of Medicine, McMaster University, and Population Health Research Institute, Hamilton, ON, Canada
    J Thromb Haemost 8:101-6. 2010
    ....
  42. ncbi request reprint Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial
    S Schulman
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    N Engl J Med 342:1953-8. 2000
    ..The length of time after an episode of venous thromboembolism during which the risk of newly diagnosed cancer is increased is not known, and whether vitamin K antagonists have an antineoplastic effect is controversial...
  43. ncbi request reprint Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran
    Sam Schulman
    Coagulation Unit, Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    N Engl J Med 349:1713-21. 2003
    ..For many patients with venous thromboembolism, secondary prevention with vitamin K antagonists is not extended beyond six months, since the risk of recurrence may be outweighed by the risk of major bleeding...
  44. doi request reprint Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
    ..Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor...
  45. doi request reprint Apixaban in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 364:806-17. 2011
    ..Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients...
  46. doi request reprint Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
    Alexander G G Turpie
    McMaster University, Hamilton, Ontario L8L 2X2, Canada
    Lancet 373:1673-80. 2009
    ..We aimed to test the efficacy and safety of oral rivaroxaban for the prevention of venous thromboembolism after total knee arthroplasty...
  47. ncbi request reprint A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I
    H Eriksson
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Thromb Haemost 1:41-7. 2003
    ..Oral ximelagatran appears to be a promising alternative to current anticoagulant therapy to limit the progression of acute DVT, and it seems to possess a wide therapeutic window...
  48. ncbi request reprint Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran
    Henry Eriksson
    Department of Medicine, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    Thromb Haemost 94:522-7. 2005
    ..Long-term use of oral ximelagatran, without coagulation monitoring or dose adjustment, should be feasible and well tolerated in a wide cross-section of patients for the secondary prevention of VTE...
  49. doi request reprint Low PAI-1 activity in relation to inflammatory parameters, insulin profile and body mass index
    A Agren
    Department of Medicine, Karolinska Institute, Stockholm, Sweden
    J Intern Med 264:586-92. 2008
    ..The purpose of this study was to investigate if patients with low PAI-1 activity have a lack of inflammatory response or a low insulin level...
  50. ncbi request reprint Unresolved issues in anticoagulant therapy
    S Schulman
    Coagulation Unit, Division of Hematology, Department of Medicine, Karolinska Hospital, Sweden
    J Thromb Haemost 1:1464-70. 2003
    ..0-2.5 in combination with low-dose aspirin, but is it really cost-effective? Finally, many controversies exist regarding anticoagulation during pregnancy...
  51. ncbi request reprint Oral anticoagulation in venous thromboembolism: decisions based on more than mere feelings
    S Schulman
    Department of Haematology and Infectious Disease, Karolinska Hospital, Stockholm, Sweden
    J Intern Med 245:399-403. 1999
    ..The optimal treatment regimen is individualized, taking into account a variety of risk factors, and re-evaluated regularly in case of prolonged therapy...
  52. ncbi request reprint Novel anticoagulant agents: introduction
    S Schulman
    Department of Medicine, Coagulation Unit, Division of Hematology, Karolinska Hospital, Stockholm, Sweden
    J Intern Med 254:308-12. 2003
    ..This introduction attempts to explain the different mechanisms of action on a broad scale, and also includes a brief look at effects on inflammation and cancer...
  53. ncbi request reprint Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate
    A Agren
    Department of Hematology, Coagulation Unit, Karolinska University Hospital, S 171 76 Stockholm, Sweden
    Thromb Res 119:715-21. 2007
    ..The aim of this study was to investigate prospectively whether low PAI-1 activity increases the risk for perioperative bleeding in patients undergoing transurethral resection of prostate, an organ with high fibrinolytic activity...
  54. ncbi request reprint Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery
    S Schulman
    Coagulation Unit, Department of Haematology, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 5:96-100. 1999
    ..Thus, continuous infusion with this highly purified factor IX concentrate with improved viral safety is effective for surgery in haemophilia B...
  55. ncbi request reprint Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis
    A Agren
    Department of Hematology, Coagulation Unit, King Gustaf V Research Institute, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 4:201-8. 2006
    ..Prospective studies of the epidemiology and clinical significance of low plasminogen activator inhibitor type 1 (PAI-1) activity are lacking...
  56. ncbi request reprint Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness
    S Schulman
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    Semin Thromb Hemost 26:421-4. 2000
    ..The only indications discussed here are hemophilia A or B with inhibitors or acquired hemophilia. Different recommendations may apply for other indications...
  57. ncbi request reprint Experiences with continuous infusion of recombinant activated factor VII
    S Schulman
    Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    Blood Coagul Fibrinolysis 9:S97-101. 1998
    ..The question of optimal monitoring needs further attention. Haemorrhagic complications were significantly less frequent when treatment was combined with the antifibrinolytic tranexamic acid...
  58. ncbi request reprint Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial
    Mark A Crowther
    McMaster University, Hamilton, Ontario, Canada
    Ann Intern Med 150:293-300. 2009
    ..Low-dose oral vitamin K decreases the international normalized ratio (INR) in overanticoagulated patients who receive warfarin therapy. Its effects on bleeding events are uncertain...
  59. ncbi request reprint Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    J P Antovic
    Coagulation Research, Department of Surgical Sciences, Karolinska University Hospital, Stockholm, Sweden
    Scand J Clin Lab Invest 64:745-51. 2004
    ..The relationship between the TAFI activation pathway and bleeding complications associated with hemophilia A, hemophilia B and VWD requires further investigation...
  60. ncbi request reprint A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders
    S Schulman
    Department of Hematology, Stockholm, Sweden
    Haemophilia 8:129-35. 2002
    ..For other genotypes, the decision regarding duration of therapy has to be based on the tolerance of the individual patient together with experiences from other studies...
  61. doi request reprint Supplemental patient education for patients taking oral anticoagulants: systematic review and meta-analysis
    P Y H Wong
    Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 11:491-502. 2013
    ..We systematically reviewed the effect of supplemental patient education vs. usual care on hemorrhage, thromboembolic events (TEEs), time in therapeutic range (TTR) and knowledge test scores for all oral anticoagulants...
  62. ncbi request reprint Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series
    T E Warkentin
    Departments of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 9:2389-96. 2011
    ..Although reports of the use of fondaparinux for this indication have thus far been favorable, the diagnosis of HIT in most cases was not based on definitive laboratory confirmation of heparin-dependent, platelet-activating antibodies...
  63. ncbi request reprint Haemostatic and replacement therapy in von Willebrand disease
    S Schulman
    Coagulation Unit, Department of Haematology and Infectious Disease, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 5:57-9. 1999
    ..The choice depends on the type of haemorrhage, the severity of the disease, presence of inhibitors, availability and cost. Some of these aspects are reviewed here...
  64. ncbi request reprint Duration of anticoagulants in acute or recurrent venous thromboembolism
    S Schulman
    Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    Curr Opin Pulm Med 6:321-5. 2000
    ..Many studies on the influence of biochemical factors in the risk of recurrence have also been published recently. This review should be helpful in-the individual decision on how to tailor the duration of anticoagulation...
  65. ncbi request reprint Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A
    J Antovic
    Coagulation Research, Department of Surgical Sciences, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 7:557-60. 2001
    ..In this paper we use new nomenclature for TAFI, and we believe that this recommended terminology for different forms of TAFI can simplify further standardization in TAFI investigation...
  66. ncbi request reprint Hypercoagulability preceding cancer. Are anticoagulants also antineoplastic?
    S Schulman
    Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 3:581-3. 2005
  67. ncbi request reprint The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Duration of Anticoagulation Study Group
    S Schulman
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    Wien Med Wochenschr 149:66-9. 1999
    ..In order to find the optimal balance of anticoagulation, avoiding recurrent events as well as major hemorrhage, it is important to know the impact of different risk factors over time...
  68. ncbi request reprint Continuous infusion
    S Schulman
    Department of Haematology, Coagulation Unit, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 9:368-75. 2003
    ..Future studies should address the question of minimum steady-state levels required for haemostasis, comparisons with bolus injection using a randomized design and investigate the risk of inhibitor formation...
  69. doi request reprint The absence of 'minor' risk factors for recurrent venous thromboembolism: a systematic review of negative predictive values and negative likelihood ratios
    K Meijer
    Thrombosis Service, McMaster Clinic, HHS General Hospital, Hamilton, ON, Canada
    J Thromb Haemost 7:1619-28. 2009
    ..A number of recently discussed risk factors that are not routinely used in clinical practice might be useful for the identification of patients with a low risk of recurrence...
  70. ncbi request reprint Optimal duration of oral anticoagulant therapy in venous thromboembolism
    S Schulman
    Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    Thromb Haemost 78:693-8. 1997
    ..The ideal solutions will perhaps only be achieved when we have learned how to combine the optimal duration with a time-adjusted decrease in oral anticoagulation...
  71. doi request reprint Decreasing warfarin sensitivity during the first three months after heart valve surgery: implications for dosing
    K Meijer
    Thrombosis Service, McMaster Clinic, HHS General Hospital, Hamilton, Ontario, Canada
    Thromb Res 125:224-9. 2010
    ..We sought to confirm our clinical impression and to gather data for the development of a guide to dosing these patients...
  72. ncbi request reprint Clinical practice. Care of patients receiving long-term anticoagulant therapy
    Sam Schulman
    Coagulation Unit, Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    N Engl J Med 349:675-83. 2003
  73. ncbi request reprint Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism
    Per Svensson
    Division of Emergency Medicine, Dept of Medicine, Karolinska Hospital, Stockholm, Sweden
    Hematol J 3:311-4. 2002
    ..In patients at a high risk for recurrence of VTE an initial period of regular intensity anticoagulation, followed by a low-intensity regimen, may provide effective and safe secondary prophylaxis...
  74. ncbi request reprint Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group
    S Schulman
    Coagulation Unit, Karolinska Hospital, Stockholm, Sweden
    Haemophilia 4:564-7. 1998
    ..The experience is reviewed here and compared with data from the conventional bolus dose regimen...
  75. ncbi request reprint Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Sam Schulman
    McMaster Clinics, HHS General Hospital, 237 Barton Street E, Hamilton, Ontario, Canada
    Chest 133:257S-298S. 2008
    ..Thrombolytic therapy increases the risk of major bleeding 1.5-fold to threefold in patients with acute venous thromboembolism, ischemic stroke, or ST-elevation myocardial infarction...
  76. ncbi request reprint Ximelagatran in the clinic: practical management of patients
    Sam Schulman
    Hamilton Health Sciences General Hospital, Hamilton, Ontario, Canada
    Semin Vasc Med 5:301-7. 2005
    ..The evidence for established management strategies is reviewed and, finally, practical handling of the case is considered...
  77. ncbi request reprint The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism
    James D Douketis
    McMaster University, Hamilton, Ontario, Canada
    Ann Intern Med 147:766-74. 2007
    ..The long-term risk for fatal pulmonary embolism (PE) after treatment of venous thromboembolism (VTE) may be an important factor in the decision to discontinue this treatment...
  78. doi request reprint Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study
    Mark A Crowther
    Division of Hematology and Thromboembolism, McMaster University Faculty of Health Sciences, St Joseph s Hospital, 50 Charlton Ave East, Hamilton, Ontario, Canada
    Thromb Haemost 104:118-21. 2010
    ..Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding...
  79. doi request reprint Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy
    Robby Nieuwlaat
    Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 108:1228-35. 2012
    ..4% to 4.1%]; p-value for non-inferiority=0.002; p-value for superiority=0.34). In conclusion, similar maintenance control of the INR was achieved with a simple one-step dosing algorithm and a commercial computerised management system...
  80. doi request reprint Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide
    E Jamula
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 6:1615-21. 2008
    ..The perioperative management of anticoagulation in patients who are having implantation of a pacemaker or implantable cardioverter defibrillator (ICD) is a common clinical problem in which best clinical practise is not established...
  81. ncbi request reprint Recombinant FVIIa in children with liver disease
    Maria Pettersson
    Department of Paediatrics, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm S 141 86, Sweden
    Thromb Res 116:185-97. 2005
    ..The aim of this study was to investigate the clinical and biochemical effects of recombinant activated factor VII (rFVIIa) in the treatment of bleeding in children with liver disease...
  82. ncbi request reprint Acquired hemophilia masked by warfarin therapy: report on two cases
    Bertil Uggla
    Department of Medicine, Orebro University Hospital, Orebro, Sweden
    Blood Coagul Fibrinolysis 14:769-72. 2003
    ..The special problems of keeping the balance between thrombosis and bleeding in this group of patients with need of anticoagulation due to mechanical heart valves or other thrombogenic factors are discussed...
  83. ncbi request reprint Why is factor Xa not a better target than factor IIa for therapeutic inhibition of coagulation?
    Sam Schulman
    Coagulation Unit, Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    Semin Thromb Hemost 29:33-6. 2003
    ..Conversely, the differentiated inhibition of the coagulation protease on vascular receptors may play a greater role for effects that are not traditionally considered as part of hemostasis...
  84. ncbi request reprint Pregnancy, heparin and osteoporosis
    Sam Schulman
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    Thromb Haemost 87:180-1. 2002
  85. doi request reprint Cervical artery dissection: pathology, epidemiology and management
    Yang Ki Kim
    Department of Medicine, McMaster University, Hamilton ON, Canada
    Thromb Res 123:810-21. 2009
    ..Cervical artery dissection is often treated with anticoagulants to prevent ischemic stroke. The risk-benefit ratio of anticoagulation versus antiplatelet therapy is unclear...
  86. doi request reprint Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators
    Marlene Robinson
    Department of Medicine, McMaster University, 237 Barton Street East, Hamilton, Ontario, Canada
    Pacing Clin Electrophysiol 32:378-82. 2009
    ..Low-molecular-weight heparin (LMWH) is often used; however, wound hematoma is a common complication...
  87. ncbi request reprint Acquired platelet dysfunction may be an aetiologic factor in Heyde's syndrome--normalization of bleeding time after aortic valve replacement
    M Olsson
    Department of Cardiology, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
    J Intern Med 252:516-23. 2002
    ..Despite several studies attempting to determine the prevalence and to discuss the aetiology, there are still many unanswered questions...
  88. ncbi request reprint Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity
    M A Blajchman
    Canadian Red Cross Blood Society Transfusion Service, Hamilton, Ontario
    Blood 79:1428-34. 1992
    ..The minimal thrombin-complexing ability of the mutant AT-III protein that was observed was accelerated by heparin, but to subnormal levels...
  89. ncbi request reprint Inhibition of warfarin activity by ribavirin
    Sam Schulman
    Coagulation Unit, Division of Hematology, Department of Medicine, Karolinska Hospital, S 171 76 Stockholm, Sweden
    Ann Pharmacother 36:72-4. 2002
    ..To report a case of inhibition of the effect of warfarin during treatment with ribavirin...
  90. pmc Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study
    Sigurdur Y Kristinsson
    Department of Medicine, Division of Hematology, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden
    Blood 115:4991-8. 2010
    ..0 g/L) at diagnosis. MGUS patients with (vs without) thrombosis had no excess risk of MM or Waldenström macroglobulinemia. Our findings are of relevance for future studies and for improvement of thrombosis prophylaxis strategies...
  91. doi request reprint Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugs
    Karina Meijer
    Thrombosis Service, McMaster Clinic, HHS General Hospital, Hamilton, Ontario, Canada
    Semin Thromb Hemost 34:762-71. 2008
    ..Knowledge of these risk factors helps to weigh the risk and benefit in the selection of therapy in individual patients. Moreover, some risk factors can be modified or avoided if they are recognized...
  92. doi request reprint Optimal timing of resumption of warfarin after intracranial hemorrhage
    Ammar Majeed
    Department of Hematology, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden
    Stroke 41:2860-6. 2010
    ..We performed a large retrospective cohort study to obtain more precise risk estimates...
  93. ncbi request reprint Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders
    Sam Schulman
    Coagulation Unit, Department of Medicine, Karolinska Hospital, S 171 76 Stockholm, Sweden
    Thromb Haemost 89:741-6. 2003
    ..We conclude that screening and eradication therapy for infection with H. pylori in patients with congenital bleeding disorders is an effective and economic strategy...
  94. ncbi request reprint The onerous task of comparing treatments in inhibitor patients
    Sam Schulman
    Thromb Haemost 98:710-2. 2007
  95. ncbi request reprint Optimal reversal of vitamin K antagonists
    Sam Schulman
    Thromb Res 119:15-6. 2007
  96. ncbi request reprint Limited protective effect of the CCR5Delta32/CCR5Delta32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus
    Astrid K N Iversen
    Department of Medical Microbiology and Immunology, Arhus University School of Medicine, Denmark
    J Infect Dis 187:215-25. 2003
    ..Sequence comparisons indicate that X4 virus can be selected in vivo due to either absence of CCR5 receptors or relative increase of CXCR4 receptors...
  97. ncbi request reprint [There is evidence for prolonged low-intensity warfarin therapy after venous thrombosis]
    Sam Schulman
    Centrum för hematologi, Karolinska sjukhuset, Stockholm
    Lakartidningen 100:2118-21. 2003
  98. ncbi request reprint [Low molecular weight heparin--a safer anticoagulant in thrombosis and cancer]
    Sam Schulman
    Centrum för hematologi, Karolinska Universitetssjukhuset Solna
    Lakartidningen 101:1712-5. 2004
  99. ncbi request reprint Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Mark N Levine
    Henderson Research Centre, 711 Concession St, Hamilton, Ontario L8V 1C3
    Chest 126:287S-310S. 2004
    ..In terms of treatment decision making for anticoagulant therapy, bleeding risk cannot be considered alone, ie, the potential decrease in thromboembolism must be balanced against the potential increased bleeding risk...
  100. ncbi request reprint Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis
    Marie Cullberg
    Clinical Pharmacology and Clinical Cardiovascular, AstraZeneca R and D Molndal, Molndal, Sweden
    Clin Pharmacol Ther 77:279-90. 2005
    ....